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Type 2 diabetes mellitus (T2DM) and insulin resistance (IR) increase colon cancer risk. Antidiabetic drugs stabilizing incretin
hormones, such as inhibitors of dipeptidyl peptidase-4 activity (DPP4i), may affect colon carcinogenesis; however, the data
remain controversial. Therefore, the authors studied whether long-term administration of the DPP4i Sitagliptin (SITA) affects
1,2-dimethylhydrazine (DMH)-induced colon carcinogenesis. Male F344 rats fed a high-fat (HF) diet promoting colon carcino-
genesis and IR, were induced with DMH (100 mg/kg 3 2 times). One week later, the animals were allocated to two groups:
one continuing with HF diet (controls; n 5 8) and one receiving SITA (n 5 8) mixed in the diet (260 ppm). Body weight, food
consumption and glycemia were not affected by SITA. Fifteen weeks after DMH, the number of the precancerous lesions
mucin-depleted foci (MDF) was significantly lower in rats treated with SITA [MDF/colon: 9.5 6 0.9 and 6.4 6 0.9 in controls
(n 5 8) and SITA groups (n 5 8), respectively; means 6 SE, p < 0.05]. Reactive oxygen species in the blood were also signifi-
cantly lower in the SITA group [6.75 6 0.69 and 5.63 6 0.75 (H2O2 in mM) in controls (n 5 5) and SITA (n 5 6), respectively;
means 6 SE, p < 0.05]. Rats treated with SITA had a lower DPP4 activity in the intestine but not in the plasma. Intestine
growth morphometric parameters and colon proliferation, as proliferating cell nuclear antigen expression, were not affected by
SITA. In conclusion, the results suggest a protective effect of DPP4i against colon carcinogenesis that could be exploited in
chemoprevention trials.
Colon cancer and insulin resistance (IR), a metabolic deregu-
lation predisposing to Type 2 diabetes mellitus (T2DM), are
affected by similar diet and lifestyle factors (e.g., calorie-rich
food and body and abdominal fatness together with low
physical activity).1,2 Interestingly, both IR and T2DM patients
are at increased risk of colon cancer.1,2
Inhibitors of dipeptidyl peptidase-4 (DPP4i), as well as
long-acting glucagon-like peptide-1 (GLP-1) receptor ago-
nists, have been recently used for pharmacological treatment
of T2DM.3 DPP4 is the enzyme involved in the degradation
of GLP-1, the gut-derived incretin hormone stimulating
insulin and suppressing glucagon secretion, and of GLP-2,
which is trophic for the intestinal mucosa.4
The possibility that incretin-based therapies may affect co-
lon cancer has been investigated; however, the data are frag-
mented, and only few studies have explored the relationship
between DPP4i and colon carcinogenesis.4–9 GLP-1 has been
reported to inhibit cell growth and increase apoptosis in co-
lon cancer cells, suggesting a protective effect against cancer.7
However, GLP-1 analogs have also been reported to increase
intestinal proliferation, a potentially dangerous effect for car-
cinogenesis.5,8 As for GLP-2, it has been reported that it did
not affect carcinogenesis in Min mice, a genetic model of in-
testinal tumorigenesis.6 However, GLP-2 increased dysplasia
and carcinogenesis in other experimental models,4 thus sug-
gesting an opposite effect to GLP-1. Therefore, it is possible
to speculate that when the half-life of both peptides is
increased by DPP4i, their overall effect on the intestine may
be null. Accordingly, most reports indicate that DPP4i
neither affect intestinal proliferation in rodents5,8 nor affect
colon carcinogenesis in mice, at least when high dosages are
administered for a short period of time.5 Moreover, the
protein DPP4 shares high homology with the fibroblast acti-
vation protein (FAP), a protease expressed by tumor-associ-
ated fibroblasts involved in tumorigenesis, angiogenesis
and metastasis.9–11 Accordingly, DPP4i, as well as more
specific inhibitors of FAP, inhibit cancer growth, suggesting a
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protective effect of DPP4i independent from glycemic mecha-
nisms.9–11
Given these considerations and the therapeutic efficacy of
DPP4i in T2DM, associated with increased colon cancer
risk,2,3 we hypothesized that Sitagliptin (SITA) administered
chronically at a dose similar to the therapeutic range might
actually decrease colon carcinogenesis. We tested this hypoth-
esis in 1,2-dimethylhydrazine (DMH)-induced rats, meas-
uring the precancerous lesions mucin-depleted foci (MDF) as
endpoint of colon carcinogenesis.12 Rats were fed high-fat
(HF) diet promoting IR and colon carcinogenesis.13 In addi-
tion, as DPP4i may affect oxidative stress,14 which contrib-
utes to the carcinogenesis process, we also tested the effect of
SITA on reactive oxygen species (ROS) in the blood. Gross
metabolic parameters and growth effects on the small intes-
tine and colon were also determined.
Material and Methods
Diet composition
The HF diet composition (23% corn oil and 32% sucrose, w/
w) is based on the AIN76 diet, as reported.15 SITA (Januvia,
MSD, UK) was added to the HF diet at 260 ppm (260 mg/kg
of diet/day). Because rats eat 11 g of diet/day and weight
about 270 g, the estimated dosage of SITA is about 10 mg/kg
body weight. On the basis of FDA preclinical studies and
considering the different metabolic rate between rats and
humans, this dose corresponds to the therapeutic human
dose of 100 mg/day.8,16,17
Animals and induction of carcinogenesis
Male F344 rats, 4–5 weeks old at their arrival from the sup-
plier (Nossan, Milan, Italy), were fed the HF diet. At 6–7
weeks of age, rats (n 5 16) were treated with two weekly
subcutaneous injections of DMH (100 mg/kg each) to induce
colon carcinogenesis (experimental protocol approved by the
Commission for Animal Experimentation of the Italian Min-
istry of Health). Six rats were treated with an equal volume
of saline (n 5 6). One week later, both DMH- and saline-
treated rats were randomly allocated to two groups: (i) con-
tinuing with the HF diet (controls) and (ii) fed with the HF
diet containing SITA (260 ppm) until sacrifice (SITA). In
both groups, there were eight rats induced with DMH and
three rats treated with saline. Animals were sacrificed 15
weeks after DMH/saline.
Collection of the samples and DPP4 activity
The intestines (small intestine and colorectum) were excised,
flushed with saline, gently dried on a soft paper and weighed.
A segment of jejunum and the entire colorectum were also col-
lected and processed, as described below. ROS were determined
according to Garelnabi et al.18 in both whole blood and plasma.
DPP4 enzymatic activity was determined in serum as well as in
ileal mucosa homogenates measuring the production of p-nitro-
aniline (pNA; Sigma-Aldrich, Italy) in microwell plates with
150 ll of 1 mM solution of the DPP4 substrate Gly-Pro-pNA
(Sigma-Aldrich) incubated for 60 sec at 37C.5,19 Linearity of
the absorbance of pNA was verified with a standard curve, and
the activity was expressed as nanomoles of pNA produced/lg
of protein/min.
MDF determination and proliferative activity
Colorectum was longitudinally opened, fixed flat in formalin
and stained with high-iron diamine Alcian Blue to highlight
mucin production, as described.12,15 MDF determination
was performed blindly in the entire colorectum.12 A seg-
ment of the distal colon of DMH-induced rats containing
no lesions was then processed for proliferating cell nuclear
antigen (PCNA) expression to measure proliferative activity
in longitudinal crypt sections, as reported.15
Morphometric analysis of the intestines
Crypt depth and villus length were blindly determined in his-
tological sections of the jejunum stained with H&E using
ACT-2U software program (Nikon, Instruments Europe, Bad-
hoevedorp, NL) connected via a camera to the microscope
(Optiphot-2; Nikon). At least 20 well-oriented crypts and 10
villi per rat were analyzed.
Metabolic parameters
At various times during the experiment, the rats were housed
individually in metabolic cages and fasted overnight. The
next morning, glycemia was measured by a glucorefractome-
ter in blood collected from the tail vein. A satiety test was
also performed transferring overnight-fasted rats into a cage
with a weighed amount of food (standard laboratory pellets).
The amount consumed was measured at 30, 60, 90 and 120
min after addition of the pellets to the cage. Cumulative val-
ues at 120 min are given.
What’s new?
The enzyme dipeptidyl peptidase-4 (DPP4) rapidly degrades insulin-stimulating incretin hormones, making its inhibition an
appealing strategy for the treatment of type 2 diabetes mellitus and possibly colon cancer. The DPP4 inhibitor sitagliptin is of
particular interest, though its role in colon carcinogenesis is unclear. Here, chemopreventive administration of sitagliptin in
rats, at doses comparable to those used in therapeutic settings for humans with diabetes, was found to reduce precancerous
colon lesions and to lower levels of reactive oxygen species in the blood. The findings warrant further investigation of sitaglip-
tin in human chemoprevention trials for colon cancer.
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Statistical analysis
Comparisons among the four different groups [also including
the saline-treated rats (both SITA and controls)] were per-
formed with two-way ANOVA, after verification of the ho-
mogeneity of variance, with Cochran’s and Bartlett’s tests.
We analyzed at the same time the effect of SITA (in saline-
and DMH-induced rats) and DMH (in controls and SITA-
treated rats), as well as the possible interactions between the
two treatments. When the comparison was between two
groups (DMH-induced rats treated with SITA compared to
DMH rats not treated), a t-test was performed. Level was
fixed at 0.05, two sided, in both cases. Statistical calculations
were performed using GraphPad Instat (GraphPad Software,
CA) and Statgraphics Statistical Packages (Statistical Graphic
Corporation, Rockville, MD).
Results
Body weight and metabolic parameters
Body weight was not affected by SITA treatment (Table 1); sim-
ilarly, fasting glycemia was similar between controls and SITA-
treated rats; however, DMH-induced rats had a significantly
higher glycemia than saline-treated counterparts (Table 1). The
amount of food eaten in 2 hr after overnight fasting (satiety)
was: 2.2 g 6 0.7 (4), 1.8 g 6 0.3 (3), 2.8 g 6 0.3 (6) and 3.5 g
6 0.5 (6) in saline-treated (controls and SITA) and in DMH-
induced rats (controls and SITA), respectively [means 6 SE
(determinations per group)]. The statistical analysis showed that
the effect of SITA on food consumption was null, whereas the
effect of DHM did not reach statistical significance, although a
trend toward an increase (p 5 0.059) was observed.
ROS in the blood
ROS determined at sacrifice in the blood of DMH-induced
rats were significantly lower (p < 0.05) in SITA-treated rats
than in controls (Fig. 1a). A similar result, although not stat-
istically significant, was observed measuring ROS in the
frozen plasma of saline-treated rats [H2O2 in mM: 9.7 6 1.5
and 7.73 6 0.6 in controls (n 5 3) and SITA-treated rats (n
5 3), respectively (mean 6 SE)].
Colon carcinogenesis
Rats treated with SITA had a significantly lower number of
the precancerous lesions MDF in the colorectum than con-
trols (Fig. 1b), indicating a protective effect of SITA against
carcinogenesis. The number of crypts forming each focus was
not affected by SITA (data not shown).
Morphometric measurements of the intestines and DPP4
activity
The weight of the intestines, normalized on body weight, was
similar across groups (Figs. 2a and 2b). Colon proliferation,
determined as PCNA expression in DMH-induced rats, was
unchanged (Fig. 2c). The number of cells/colonic crypts was
also similar across groups (data not shown). Morphometric
measurements of the small intestine (Figs. 2d and 2e) also
did not show any effect of SITA or DMH treatment. DPP4
activity measured in ileal mucosa homogenates was signifi-
cantly lower in rats treated with SITA than in controls (Fig.
2f). On the contrary, DPP4 activity in the serum was not sig-
nificantly modified by SITA (data not shown).
Discussion
The main finding of our study is that SITA, a DPP4i with
clinical effectiveness in the treatment of human T2DM,
decreases colon carcinogenesis and blood ROS levels when
administered to rats at a dosage similar to the human thera-
peutic setting.
The results were obtained measuring the precancerous
lesions MDF in DMH-induced rats, a robust experimental
model to identify drugs or dietary treatments with chemopre-
ventive activity against colon cancer.1,5,12,13 Rats were fed a
Table 1. Rat body weight and fasting glycemia during the various phases of the experiment
Groups
Start of the experiment,
before DMH/saline
After DMH/saline
before SITA After SITA
Body weight (g)
DMH SITA (8) 124.0 6 4.1 (16) 164.9 6 5.7 (8) 358 6 10 (8)
Controls (8) 154.6 6 4.9 (8) 352 6 10 (8)
Saline SITA (3) 123.7 6 3.4 (6) 168.0 6 4.4 (8) 380 6 12 (8)
Controls (3) 178.3 6 5.8 (8) 368 6 15 (8)
Glycemia (mg/dl)
DMH SITA (8) 86.3 6 0.5 (3) 95 6 3.3 (4) 99.8 6 5.6 (11)1
Controls (8) 82 6 6 (4) 101.1 6 4.6 (10)1
Saline SITA (3) ND 87.3 6 2.3 (3)
Controls (3) ND 83.7 6 7.6 (4)
Numbers in parentheses represent the number of animals/determinations per group.
1Significantly different from saline-treated rats at the same time after SITA (p 5 0.046 with two-way ANOVA). Abbreviation: Not determined.
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HF/high-sucrose diet, mimicking human diets leading to
both increased colon carcinogenesis and IR.13
To the best of our knowledge, this is the first study
reporting a protective effect of the DPP4i SITA on intestinal
carcinogenesis.
Recently, Kissow et al.5 reported that SITA administered
to mice at a dose of 400 mg/kg (about 40 times higher than
the dose we used) did not affect DMH-induced carcinogene-
sis. At variance with our long-term SITA administration (13–
14 weeks), in the report of Kissow et al., the drug was
administered for a much shorter period (6–7 weeks), a factor
that could have hampered the potential positive effects of
SITA. Moreover, in the study of Kissow et al., carcinogenesis
was induced with several repeated injections of DMH (12
weekly treatments), administering SITA only after a long
period (16 weeks) from the last injection with DMH.5 On the
contrary, we administered SITA starting from the very early
steps of carcinogenesis, that is, few days after the second
(and last) treatment with DMH, and thus allowing SITA to
counteract the process of carcinogenesis from the very begin-
ning. Interestingly, the effect of SITA on carcinogenesis
occurs independently from variation of proliferation and
morphometric parameters of the colon and small intestine.
This result is in agreement with previous reports document-
ing that NN-7201, a DPP4i administered at a dosage similar
to that we used, did not affect intestinal growth in rats with
normal colon.8 However, it has also been reported that SITA
enhanced intestinal adaptation in mice with bowel resection,
an effect that could be explained with the pathological condi-
tion of those mice and with the high dosage of SITA causing
Figure 1. (a) Blood ROS in DMH-induced rats treated with Sitagliptin (SITA) or not (controls). Values are mean 6 SE, n 5 6; *p 5 0.045
comparing SITA with controls. (b) MDF/colon in DMH-induced rats treated with SITA or not (controls). Values are mean 6 SE, n 5 8; *p 5
0.02 comparing SITA with controls (t-test).
Figure 2. Colon weight/body weight % (a) and small intestinal weight/body weight % (b) in the different groups. (c) Expression of PCNA as
labeling index (LI: number of labeled cells/cells counted 3 100) in the colon mucosa of DMH-induced rats treated or not with SITA; bars
are mean 6 SE, n 5 7 and 8 in controls and SITA-treated rats, respectively. (d and e) Depth of crypts and length of the villi in the small
intestine, respectively, in the different groups; bars are mean 6 SE, n 5 3 and 8 in each group of the saline and DMH-treated rats, respec-
tively. (f) DPP4 activity (nanomoles of pNA produced/lg of protein/min) in the ileal mucosa; n 5 2, 3, 6 and 5 in saline (controls and SITA)
and DMH-treated (controls and SITA) rats, respectively. *p 5 0.01 comparing SITA with controls in both saline and DMH-treated rats (two-
way ANOVA). In each graph, white bars represent controls, and the black bars represent SITA-treated rats.
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increased level of GLP-2 (actually, GLP-1 was not tested in
that study).20 It is also possible that in our experimental con-
ditions, SITA exerts specific inhibitory effects on preneoplas-
tic cells. Accordingly, recent data showed that GLP-1 has
protective effects on colon cancer cell lines and in trans-
planted tumors7; thus, although we did not test the level of
GLP-1 in our rats, it would be possible to speculate that the
beneficial effect of SITA that we found is partially related to
an increase in GLP-1. Although we did not find changes of
DPP4 enzymatic activity in the serum, the enzymatic activity
in the ileum was significantly lower in the rats receiving
SITA, thus suggesting a local effect of this drug. Accordingly,
a recent study in mice treated with various doses of SITA
reported that relatively low doses of this drug, as in our
study, inhibited DPP4 activity in the intestine but not in the
plasma.19
On the other hand, it is also interesting to consider that
DPP4 shares high homology with the FAP expressed by tu-
mor-associated fibroblasts and related to increased tumori-
genesis.9,10 Overexpression of FAP has been reported in
colon carcinogenesis,10 and inhibitors of FAP have been eval-
uated in Phase II trials for metastatic colon cancer.11 It has
also been reported that vildagliptin, a DPP4i related to SITA,
as well as synthetic inhibitors of FAP inhibit lung tumorigen-
esis,9 suggesting a protective effect of DPP4i independent
from glycemic mechanisms.
In fact, in our study, the effect of SITA on carcinogenesis
occurred without any associated metabolic action on either
body weight or blood glucose. Incidentally, we observed that
the DMH-treated rats (irrespectively from the SITA treat-
ment) had higher glycemia than their saline counterpart. A
similar effect of the carcinogen DMH on glucose blood levels
has been reported in the past; however, besides a generic
toxic effect of DMH on glucose metabolism, no clear expla-
nation exists for this phenomenon, which certainly deserves
further investigation.21
We also found that rats treated with SITA had blood ROS
lower than controls, suggesting that SITA might also work as
a scavenging or an antioxidant compound, helping to limit
ROS-mediated tissue damages. In agreement with our result,
Vaghasiya et al.14 demonstrated that SITA protects against
ROS-mediated renal damage induced by hypoxia in rats.
Similar protective effects against ROS were reported for GLP-
1 in reducing cardiac ischemia reperfusion injuries.22
Our study has some limitations. In fact, the results have
been obtained with a single dosage of SITA administered for
only one period of time. However, the results are clear-cut,
and the level of MDF inhibition is comparable to that we
observed with known colon cancer chemopreventive regi-
mens (e.g., low-fat diet or caloric restriction).23,24 Therefore,
even with the due caution in extrapolating results from ani-
mals to humans, these data may be particularly relevant in
T2DM patients considered at risk for colon cancer. In addi-
tion, provided further experimental studies to understand the
mechanism of action of SITA on colon carcinogenesis, its
chemopreventive activity might also justify intervention trials
in nondiabetic patients at risk for colon cancer such as
patients operated for polyps or colon cancer. In fact, the
almost absent risk of hypoglycemia allows the indication of
DPP4i to nondiabetic patients as well. Besides, although the
duration of available clinical trials with DPP4i is too short to
provide any reliable information on the effect of these drugs
on the incidence of cancer in humans, no reasons for con-
cern have emerged so far.25
In conclusion, the results of our study show that SITA, a
DPP4i, given chronically to DMH-induced rats reduces pre-
cancerous lesions in the colon and blood ROS, suggesting a
protective effect toward the carcinogenesis processes, which
deserves further investigation.
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